130 related articles for article (PubMed ID: 6507372)
1. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
DeSimone PA; Gams R; Bartolucci A
Am J Clin Oncol; 1984 Oct; 7(5):517-22. PubMed ID: 6507372
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of mitoxantrone in advanced colorectal cancer.
Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
[No Abstract] [Full Text] [Related]
3. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
[No Abstract] [Full Text] [Related]
4. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Arseneau JC; Schoenfeld DA; Borden EC
Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
Gams RA; Nelson O; Birch R
Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
[No Abstract] [Full Text] [Related]
7. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
Knight WA; Von Hoff DD; Neidhart JA; Tranum BL; Fabian C; Jones SE
Invest New Drugs; 1983; 1(2):181-4. PubMed ID: 6678866
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.
Williams SD; Birch R; Velez-Garcia E; Gams R
Invest New Drugs; 1985; 3(3):311-3. PubMed ID: 4066226
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone in malignant melanoma.
Presant CA; Gams R; Bartolucci A
Cancer Treat Rep; 1984 Jun; 68(6):903-5. PubMed ID: 6733704
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
Stuart-Harris RC; Smith IE
Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
[TBL] [Abstract][Full Text] [Related]
12. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Valdivieso M; Umsawasdi T; Spitzer G; Chiuten DF; Booser DJ; Dhingra HM; Bodey GP
Am J Clin Oncol; 1984 Jun; 7(3):241-4. PubMed ID: 6328968
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
[TBL] [Abstract][Full Text] [Related]
15. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of metoprine in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Currie V
Cancer Treat Rep; 1981; 65(1-2):127-8. PubMed ID: 7226162
[No Abstract] [Full Text] [Related]
17. Mitoxantrone in advanced renal cancer: a phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
van Oosterom AT; Fosså SD; Pizzocaro G; Bergerat JP; Bono AV; De Pauw M; Sylvester R
Eur J Cancer Clin Oncol; 1984 Oct; 20(10):1239-41. PubMed ID: 6541582
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of 10-deaza-aminopterin in patients with advanced colorectal cancer.
Cheng EW; Currie VE; Yagoda A
Am J Clin Oncol; 1983 Aug; 6(4):469-71. PubMed ID: 6869317
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
van Oosterom AT; Fosså SD; Mulder JH; Calciati A; de Pauw M; Sylvester R
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1013-4. PubMed ID: 4065174
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
